Log In
BCIQ
Print this Print this
 

AndexXa, IndexXa, andexanet alfa (PRT064445, PRT4445)

  Manage Alerts
Collapse Summary General Information
Company Portola Pharmaceuticals Inc.
DescriptionModified human Factor Xa protein that acts as a decoy to target and sequester Factor Xa inhibitors
Molecular Target
Mechanism of ActionReverse anticoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentRegistration
Standard IndicationBleeding
Indication DetailsReverse anticoagulant activity of Factor Xa inhibitors
Regulatory Designation U.S. - Breakthrough Therapy (Reverse anticoagulant activity of Factor Xa inhibitors);
U.S. - Orphan Drug (Reverse anticoagulant activity of Factor Xa inhibitors);
U.S. - Priority Review (Reverse anticoagulant activity of Factor Xa inhibitors)
PartnerBristol-Myers Squibb Co.;
Pfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

8

$105.0M

$20.0M

$90.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today